Published On: Mon, May 9th, 2016
Uncategorized | By Sylvia Delisle

Can-Fite Biopharma Ltd (CANF) Analyst Review

A number of investment brokers have recently updated their price targets on shares of Can-Fite Biopharma Ltd (CANF). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/04/2016 – Can-Fite Biopharma Ltd had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 6 price target on the stock.

03/30/2015 – Can-Fite Biopharma Ltd was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 2.4 price target on the stock.

The share price of Can-Fite Biopharma Ltd (CANF) was up +5.17% during the last day of trading, with a day high of 2.75. 52534 shares were traded during the last session.

The stock’s 50 day moving average is 2.88 and its 200 day moving average is 2.74. The stock’s market capitalization is 29.44M. Can-Fite Biopharma Ltd has a 52-week low of 1.46 and a 52-week high of 7.85.

View other investors thoughts on Can-Fite Biopharma Ltd with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.

Receive News & Ratings Via Email

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: